Savara is focusing on innovative drugs for the treatment of serious and life-threatening rare respiratory diseases. Disease targets in our pipeline include MRSA in cystic fibrosis, pulmonary alveolar proteinosis, acute respiratory distress syndrome and diffuse alveolar hemorrhage. The establishment and progress of our development programs are based on repositioning of known drugs, on an extensive outsourcing strategy and on international strategic alliances. For selected programs in our pipeline we are interested in discussing co-development, partial or global out-licensing and co-investments. We also engage in discussions with a broader scope like strategic alliances and various corporate transactions.
If you are interested in discussing a potential collaboration, please contact Taneli Jouhikainen at email@example.com.